The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, yet its legacy within the broader market now raises questions about long-term returns . Copycat versions are eroding patent protection , leading to concerns that supporting companies significantly dependent to Viagra's former standing could be a speculative strat